Kümler, Iben <br/><br/>
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.  [electronic resource] 

 -  BMC cancer  Feb 2015 
 - 78 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-015-1072-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Breast Neoplasms--drug therapy<br/>Camptothecin--administration & dosage<br/>DNA Topoisomerases, Type I--genetics<br/>Drug Administration Schedule<br/>Female<br/>Gene Dosage<br/>Genetic Markers--genetics<br/>Humans<br/>Irinotecan<br/>Neoplasm Metastasis<br/>Prospective Studies<br/>Receptor, ErbB-2--genetics<br/>Topoisomerase I Inhibitors--administration & dosage<br/>Treatment Outcome